Novartis to build $23B radioligand therapy site

Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…

AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Merck reorganizes, creating dedicated oncology business unit / 3 months

Servier to acquire Day One Biopharma for $2.5B / 2 months

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months

Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 2 months

Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months

TTLC 2026 highlights advanced NSCLC symposia and emerging data / 3 months

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days